Nutriband Inc. (NTRB)

Market Cap	82.85M
Revenue (ttm)	2.02M
Net Income (ttm)	-6.85M
Shares Out	11.11M
EPS (ttm)	-0.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,390
Open	7.47
Previous Close	7.38
Day's Range	7.25 - 7.63
52-Week Range	2.22 - 11.78
Beta	0.46
Analysts	Buy
Price Target	13.00 (+74.26%)
Earnings Date	Dec 4, 2024

About NTRB

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: NTRB
• Website: https://www.nutriband.com

Financial Performance

In 2023, Nutriband's revenue was $2.09 million, an increase of 0.27% compared to the previous year's $2.08 million. Losses were -$5.49 million, 22.3% more than in 2022.

Analyst Forecast

According to one analyst, the rating for NTRB stock is "Buy" and the 12-month stock price forecast is $13.0.

Price Target

$13.0

(74.26% upside)

Analyst Consensus: Buy